1. Home
  2. INLX vs LPCN Comparison

INLX vs LPCN Comparison

Compare INLX & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellinetics Inc.

INLX

Intellinetics Inc.

N/A

Current Price

$4.17

Market Cap

21.6M

Sector

Technology

ML Signal

N/A

Logo Lipocine Inc.

LPCN

Lipocine Inc.

HOLD

Current Price

$1.51

Market Cap

18.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INLX
LPCN
Founded
1996
1997
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.6M
18.7M
IPO Year
2013
2011

Fundamental Metrics

Financial Performance
Metric
INLX
LPCN
Price
$4.17
$1.51
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $5.00
AVG Volume (30 Days)
26.2K
★ 1.6M
Earning Date
11-09-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
$11,336.00
★ $1,976,677.00
Revenue This Year
$14.57
N/A
Revenue Next Year
N/A
$18.02
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$4.01
$1.40
52 Week High
$9.45
$12.37

Technical Indicators

Market Signals
Indicator
INLX
LPCN
Relative Strength Index (RSI) 39.53 33.46
Support Level $4.12 N/A
Resistance Level $5.80 $2.50
Average True Range (ATR) 0.61 0.11
MACD -0.05 -0.00
Stochastic Oscillator 6.20 29.73

Price Performance

Historical Comparison
INLX
LPCN

About INLX Intellinetics Inc.

Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Software and Document Services. The Software segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Services offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Services Segment.

About LPCN Lipocine Inc.

Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Share on Social Networks: